Limes Schlosskliniken AG: directors' dealings · Germany · BaFin

About Limes Schlosskliniken AG

Limes Schlosskliniken AG is a German listed healthcare group focused on private psychiatry and psychiatric rehabilitation, traded on Xetra/Frankfurt (DAX/MDAX/SDAX) in Germany. The company operates in a specialized niche of inpatient mental health care, offering premium, individualized treatment programs for psychological disorders. Its patient mix includes private patients, publicly insured patients with reimbursement, and patients covered by public aid. From an equity analyst perspective, the investment case rests on a rare specialist positioning, relatively high treatment intensity, and the structural undersupply of mental health capacity, balanced against staff shortages, regulatory complexity, and the execution risk of opening new clinics. ([limes-schlosskliniken.de](https://www.limes-schlosskliniken.de/app/uploads/2025/05/Annual-Report-2024-LIMES-Schlosskliniken.pdf)) The group was founded in 2005, originally under the name GMF Capital AG, and was renamed Limes Schlosskliniken AG in 2015, at the same time relocating its head office to Cologne. Limes Schlosskliniken AG serves as the central holding company of the group, overseeing strategic, financial and operational management, as well as brand development, marketing, acquisition and the development of new clinic sites. Clinic operations are run from Cologne. ([limes-schlosskliniken.de](https://www.limes-schlosskliniken.de/app/uploads/2025/05/Annual-Report-2024-LIMES-Schlosskliniken.pdf)) Limes Schlosskliniken currently operates a multi-site platform in Germany and nearby markets. Its locations include Mecklenburgische Schweiz in Teterow/Teschow, Fürstenhof in Bad Brückenau, Abtsee in the Berchtesgadener Land, and Bergisches Land in Lindlar, plus CLINICUM ALPINUM in Gaflei, Liechtenstein, and the Paracelsus Recovery Clinic in Zurich/London. The group states that it has around 400 high-quality treatment places across six clinic locations. Its treatment portfolio covers anxiety disorders, obsessive-compulsive disorders, ADHD/ADD, sleep disorders, personality disorders, chronic pain and sports psychiatry. ([limes-schlosskliniken.de](https://www.limes-schlosskliniken.de/app/uploads/2025/05/Annual-Report-2024-LIMES-Schlosskliniken.pdf)) Competitively, Limes Schlosskliniken benefits from a premium, high-service clinical model and a market environment in which demand for mental health treatment remains structurally strong while public-sector capacity is constrained by long waiting times. That said, the company is still exposed to industry-wide pressure on qualified personnel, cost inflation, and the ramp-up profile of newly opened facilities. Its model is therefore best understood as a specialized healthcare platform with operating leverage potential, but also with meaningful execution sensitivity. ([limes-schlosskliniken.de](https://www.limes-schlosskliniken.de/app/uploads/2025/05/Annual-Report-2024-LIMES-Schlosskliniken.pdf)) Recent developments have been important. The investor relations page shows the opening of Abtsee in June 2025 and Bergisches Land in July 2025, while a February 2026 trading update reported strong 2025 growth and indicated that Abtsee was already contributing positively from January 2026. The company also disclosed a directors’ dealings notification in April 2026, consistent with Germany’s MAR Article 19 transparency framework overseen by BaFin. ([limes-schlosskliniken.de](https://www.limes-schlosskliniken.de/en/investor-relations/?utm_source=openai))